Liquidia Corporation (LQDA)
14.09
0.08 (0.57%)
At close: Jan 28, 2025, 2:01 PM
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
It also distributes generic treprostinil injection in the United States.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation
| Country | United States |
| IPO Date | Jul 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Dr. Roger A. Jeffs Ph.D. |
Contact Details
Address: 419 Davis Drive Morrisville, North Carolina United States | |
| Website | https://www.liquidia.com |
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819576 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| Employer ID | 85-1710962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Roger A. Jeffs Ph.D. | Chief Executive Officer & Director |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
| Dr. Ginger Denison | Co-Founder |
| Dr. Rajeev Saggar M.D. | Chief Medical Officer |
| Jason Adair | Chief Business Officer |
| Michael Hunter | Senior Vice President of Manufacturing Operations |
| Russell Schundler | General Counsel & Corporate Secretary |
| Sarah Krepp SPHR | Vice President of People & Culture |
| Scott Moomaw | Chief Commercial Officer |
| William R. Kenan Jr. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 23, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |